Orexigen Therapeutics
Acquired
- Headquarters
- USA, California
- Employees
- 51–200
- Founded
- 2004
- Business Model
- B2B
- Website
- orexigen.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series CNov 2006
About
Orexigen Therapeutics was a La Jolla, California-based biopharmaceutical company focused on treatments for obesity. The company developed Contrave (naltrexone/bupropion extended-release), an FDA-approved prescription weight-loss medication. Orexigen filed for Chapter 11 bankruptcy in March 2018 and its assets were acquired by Nalpropion Pharmaceuticals.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account